Ifthikar Mariam Anjum, Rajanbabu Anupama, Nair Indu R, Murali Vinita, Nair Anjaly S
Department of Gynecologic Oncology, Amrita Institute of Medical Sciences, Amrita University, Kochi, Kerala, India.
Department of Pathology, Amrita Institute of Medical Sciences, Amrita University, Kochi, Kerala, India.
South Asian J Cancer. 2020 Jul;9(3):168-173. doi: 10.1055/s-0040-1721192. Epub 2021 Mar 19.
Borderline ovarian tumors (BOTs) are an intermediate form of neoplasia, between benign and malignant. The aim of this retrospective analysis is to evaluate the clinicopathological characteristic profile of BOTs and to determine the predictors of recurrence in BOTs. A retrospective review of all patients diagnosed, treated, and followed up for BOTs between 2010 and 2017 at Amrita Institute of Medical Sciences, Kerala, India, was conducted. Clinicopathological details and details of management, outcome, and survival were retrieved, and data were analyzed descriptively and for survival. A total of 103 patients were identified. During the median follow-up of 46.0 months, 15 (14.6%) patients developed recurrent disease, 6 (5.82%) had recurrence with progression to invasive carcinoma, and 9 had recurrent disease with borderline or benign histology. Mucinous tumors were found to have more recurrences than serous BOT (17.8 vs. 12.3%). Disease-related deaths (5/103 [4.9%]) were observed only in patients with progression to invasive carcinoma. Univariate analysis indicated that staging surgery was the most important prognostic factor that affected the disease-free survival ([DFS] 103 vs. 97 vs. 71 months, respectively, for complete staging vs. fertility-preserving staging vs. conservative surgery; < 0.05). Conservative surgery was associated with a higher risk of recurrence. Fertility-preserving staging surgery is an acceptable option in younger patients. The overall survival is not affected by the mode of surgery.
卵巢交界性肿瘤(BOTs)是一种介于良性和恶性之间的肿瘤形成中间形式。本回顾性分析的目的是评估BOTs的临床病理特征,并确定BOTs复发的预测因素。
对2010年至2017年期间在印度喀拉拉邦阿姆里塔医学科学研究所诊断、治疗和随访的所有BOTs患者进行了回顾性研究。检索了临床病理细节以及治疗、结局和生存的详细信息,并对数据进行了描述性分析和生存分析。
共确定了103例患者。在中位随访46.0个月期间,15例(14.6%)患者出现复发性疾病,6例(5.82%)复发并进展为浸润性癌,9例复发疾病组织学为交界性或良性。发现黏液性肿瘤的复发比浆液性BOT更多(17.8%对12.3%)。仅在进展为浸润性癌的患者中观察到疾病相关死亡(5/103 [4.9%])。单因素分析表明,分期手术是影响无病生存期的最重要预后因素(完全分期、保留生育功能分期和保守手术的无病生存期分别为103个月、97个月和71个月;P<0.05)。
保守手术与较高的复发风险相关。保留生育功能的分期手术对年轻患者是一个可接受的选择。手术方式不影响总生存期。